Potential Clinical and Economic Impacts of Cutbacks in the President’s Emergency Plan for AIDS Relief Program in South Africa
Annals of Internal Medicine · 2025-04 · 178 (4) · 457-467
DOI: 10.7326/annals-24-01104 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Internal Medicine, 2025-04. Verfasst von Aditya R Gandhi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, and Department of Medicine, NYU Grossman School of Medicin…. Hauptthemen laut MEDLINE: HIV Infections, Acquired Immunodeficiency Syndrome. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Future U.S. congressional funding for the President's Emergency Plan for AIDS Relief (PEPFAR) program is uncertain. OBJECTIVE: To evaluate the clinical and economic impacts of abruptly scaling back PEPFAR funding ($460 million) from South Africa's total HIV budget ($2.56 billion) in 2024. DESIGN: Model-based analysis of 100%, 50%, and 0% PEPFAR funding with proportional decreases in HIV diagnosis rates (26.0, 24.3, 22.6 per 100 person-years [PY]), 1-year treatment engagement (people with HIV [PWH] receiving/initiating antiretroviral therapy: 92.2%/80.4%, 87.1%/76.0%, 82.0%/71.5%), and primary prevention (4.0%, 2.2%, 0.5% reduction in incidence with no programming [1.24 per 100 PY]). DATA SOURCES: Published HIV care continuum; PEPFAR funding estimates. TARGET POPULATION: South African adults (HIV prevalence, 16.2%; incidence, 0.32 per 100 PY). TIME HORIZON: Lifetime. PERSPECTIVE: Health care sector. INTERVENTION: PEPFAR funded 100% (PEPFAR_100%), 50% (PEPFAR_50%), or 0% (PEPFAR_0%). OUTCOME MEASURES: HIV infections, life expectancy, and lifetime costs (2023 U.S. dollars). RESULTS OF BASE-CASE ANALYSIS: With current HIV programming (PEPFAR_100%), 1 190 000 new infections are projected over 10 years; life expectancy would be 61.42 years for PWH, with lifetime costs of $11 180 per PWH. Reduced PEPFAR funding (PEPFAR_50% and PEPFAR_0%) would add 286 000 and 565 000 new infections, respectively. PWH would lose 2.02 and 3.71 life-years with nominal lifetime cost reductions of $620 per PWH and $1140 per PWH that would be offset at the population level by more PWH requiring treatment for infection. RESULTS OF SENSITIVITY ANALYSIS: Countries with similar HIV prevalence and greater reliance on PEPFAR funding could experience disproportionately higher incremental infections and survival losses. LIMITATION: Budget fungibility and exact programmatic implications of reducing PEPFAR funding are unknown. CONCLUSION: Abrupt PEPFAR cutbacks would have immediate and long-term detrimental effects on epidemiologic and clinical HIV outcomes in South Africa. PRIMARY FUNDING SOURCE: National Institutes of Health.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, and Department of Medicine, NYU Grossman School of Medicine, New York, New York (A.R.G.).
- Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa (L.G.B.).
- Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut (A.D.P.).
- Medical Practice Evaluation Center, Massachusetts General Hospital; Division of Infectious Diseases, Massachusetts General Hospital; and Harvard Medical School, Boston, Massachusetts (E.P.H., A.L.C.).
- Department of Global Health, Stellenbosch University, Stellenbosch, South Africa (Y.P.).
- Medical Practice Evaluation Center, Massachusetts General Hospital; Division of Infectious Diseases, Massachusetts General Hospital; Harvard Medical School; and Division of General Internal Medicine, Massachusetts Gener…
ORCID-Profile: Aditya R Gandhi, Linda-Gail Bekker, A David Paltiel, Emily P Hyle, Andrea L Ciaranello, Yogan Pillay, Anne M Neilan
Förderung
- NIAID NIH HHS
- NICHD NIH HHS
Zitieren
APA
Gandhi, A. R., Bekker, L. G., Paltiel, A. D., Hyle, E. P., Ciaranello, A. L., Pillay, Y., Freedberg, K. A., & Neilan, A. M. (2025). Potential Clinical and Economic Impacts of Cutbacks in the President’s Emergency Plan for AIDS Relief Program in South Africa. Annals of Internal Medicine, 178(4), 457-467. https://doi.org/10.7326/annals-24-01104
Vancouver
Gandhi AR, Bekker LG, Paltiel AD, Hyle EP, Ciaranello AL, Pillay Y, et al. Potential Clinical and Economic Impacts of Cutbacks in the President’s Emergency Plan for AIDS Relief Program in South Africa. Annals of Internal Medicine. 2025;178(4):457-467. doi:10.7326/annals-24-01104
BibTeX
@article{Gandhi2025,
author = {Gandhi, Aditya R and Bekker, Linda-Gail and Paltiel, A David and Hyle, Emily P and Ciaranello, Andrea L and Pillay, Yogan and Freedberg, Kenneth A and Neilan, Anne M},
title = {Potential Clinical and Economic Impacts of Cutbacks in the President’s Emergency Plan for AIDS Relief Program in South Africa},
journal = {Annals of Internal Medicine},
year = {2025},
volume = {178},
number = {4},
pages = {457--467},
doi = {10.7326/annals-24-01104}
}
EUVIMED